Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd has released its FY25 Appendix 4G and Corporate Governance Statement, demonstrating its adherence to ASX corporate governance principles. This announcement underscores Cogstate’s commitment to transparency and regulatory compliance, which may enhance its reputation and trust among stakeholders, potentially impacting its market position positively.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that specializes in optimizing brain health assessments to aid in the development of new medicines and provide earlier clinical insights in healthcare. The company offers computerized cognitive tests and electronic clinical outcome assessment solutions, supporting biopharmaceutical companies, academic institutions, and healthcare providers globally. Cogstate focuses on providing scientifically validated digital cognitive measures for primary care physicians and consumers.
Average Trading Volume: 82,586
Technical Sentiment Signal: Buy
Current Market Cap: A$284M
For detailed information about CGS stock, go to TipRanks’ Stock Analysis page.